Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025
Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in multiple patients treated with FOG-001
Excerpt from the Press Release:
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical data demonstrating the therapeutic potential of its lead investigational Helicon™ peptide, FOG-001 – the first and only direct inhibitor of the “undruggable” β-catenin:TCF interaction – in adamantinomatous craniopharyngioma (ACP).
The ACP data, presented today as a mini-oral at the 30th Society for Neuro-Oncology (SNO) Annual Meeting and first shared at last month’s AACR-NCI-EORTC 2025 “Triple” Meeting, represent the second low-complexity Wnt/β-catenin-driven tumor subgroup – following desmoid tumors – to show tumor reductions in all patients treated to date with FOG-001 monotherapy.
ACP is a rare brain tumor that is often associated with severe endocrine, visual, and neurological complications, where unmet patient needs are high. Due to the location of tumors, surgery and radiation, the mainstays of treatment, can be challenging and carry a high risk of complications, and no approved systemic therapies exist.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?